Home
GNPX
GNPX News

Latest Genprex Inc. (GNPX) News on June 29, 2025

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

PR Newswire

4 days ago

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

PR Newswire

5 days ago

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions

MT Newswires

17 days ago

Genprex Files for Resale of 15 Million Shares

Genprex to Participate at BIO 2025 International Convention

PR Newswire

a month ago

Genprex to Participate at BIO 2025 International Convention

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

PR Newswire

a month ago

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

PR Newswire

a month ago

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

PR Newswire

2 months ago

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

PR Newswire

2 months ago

Genprex Signs Exclusive License to Additional Gene Therapy Technology with UTHealth Houston for the Treatment of Glioblastoma

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

PR Newswire

2 months ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

PR Newswire

2 months ago

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

PR Newswire

2 months ago

Genprex Signs Exclusive Technology License Agreement with New York University Langone Health for the Treatment of Mesothelioma

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

PR Newswire

2 months ago

Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings

PR Newswire

2 months ago

Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

PR Newswire

3 months ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

PR Newswire

3 months ago

Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex to Participate at BIO Europe Spring 2025

PR Newswire

4 months ago

Genprex to Participate at BIO Europe Spring 2025

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

PR Newswire

4 months ago

Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System

Genprex Provides Update on Diabetes Gene Therapy Program

PR Newswire

4 months ago

Genprex Provides Update on Diabetes Gene Therapy Program

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

PR Newswire

4 months ago

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Genprex doses first subject in expansion part of lung cancer gene therapy trial

Clinical Trials Arena

5 months ago

Genprex doses first subject in expansion part of lung cancer gene therapy trial

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

PR Newswire

5 months ago

Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Genprex Advances Cancer Trials and Diabetes Therapy

TipRanks

5 months ago

Genprex Advances Cancer Trials and Diabetes Therapy

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

PR Newswire

6 months ago

Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

MT Newswires

6 months ago

Genprex Completes Phase 1 Dose Escalation in Trial of Reqorsa Gene Therapy to Treat Lung Cancer

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

PR Newswire

6 months ago

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Genprex links with University of Michigan on lung cancer treatment

Pharmaceutical Technology

7 months ago

Genprex links with University of Michigan on lung cancer treatment

MT Newswires

7 months ago

Genprex Signs License Deal for University of Michigan's Gene Therapy to Treat Lung Cancer

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

PR Newswire

7 months ago

Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer

MT Newswires

8 months ago

Genprex Reports Positive Preclinical Data on Reqorsa Gene Therapy; Regains Nasdaq Compliance

Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

PR Newswire

8 months ago

Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Genprex to Participate in 2024 BIO Europe Conference

PR Newswire

8 months ago

Genprex to Participate in 2024 BIO Europe Conference

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma

PR Newswire

8 months ago

Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma

Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive

PR Newswire

8 months ago

Genprex Announces Sponsored Research Agreement with The University of Michigan Rogel Cancer Center and Lung Cancer Study Collaboration with ALK Positive

MT Newswires

8 months ago

Top Premarket Decliners

Genprex advances to highest dose in Phase I Acclaim-3 trial of Reqorsa

Clinical Trials Arena

8 months ago

Genprex advances to highest dose in Phase I Acclaim-3 trial of Reqorsa

MT Newswires

8 months ago

Genprex Gets Dosage Escalation Approval in Small-Cell Lung Cancer Treatment Trial; Shares Jump

Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

PR Newswire

8 months ago

Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

PR Newswire

9 months ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

PR Newswire

9 months ago

Genprex Collaborators to Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes

PR Newswire

9 months ago

Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes

Genprex Announces Formation of Mesothelioma Clinical Advisory Board

PR Newswire

9 months ago

Genprex Announces Formation of Mesothelioma Clinical Advisory Board

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

PR Newswire

10 months ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

MT Newswires

10 months ago

Genprex Plans to Create Diabetes-Focused Unit

Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes

PR Newswire

10 months ago

Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

PR Newswire

10 months ago

Genprex to Present and Participate at Upcoming September Investor and Industry Conferences

Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials

PR Newswire

10 months ago

Genprex Releases New Video Featuring Chief Medical Officer Discussing Positive Patient Outcomes in Two Lung Cancer Clinical Trials

Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

PR Newswire

10 months ago

Genprex Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

MT Newswires

10 months ago

Genprex Secures Singapore Patent for Cancer Treatment; Shares Down

Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers

PR Newswire

a year ago

Genprex Granted Patent in Singapore for Reqorsa® Gene Therapy with PD-1 Antibodies to Treat Cancers

Genprex to Present at the August Sidoti Microcap Conference

PR Newswire

a year ago

Genprex to Present at the August Sidoti Microcap Conference

Genprex Issues Stockholder Letter and Provides 2024 Corporate Update

PR Newswire

a year ago

Genprex Issues Stockholder Letter and Provides 2024 Corporate Update

NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities

PR Newswire

a year ago

NexTech Solutions Has Agreed to Acquire Rome Research Corporation to Expand Service Offerings and Enhance Mission Support Capabilities

Business Wire

a year ago

Form 8.3 - Darktrace plc

Business Wire

a year ago

Form 8.3 - International Distribution Services plc

US Supreme Court rejects Kroger challenge to Grubhub trademark win

Reuters

a year ago

US Supreme Court rejects Kroger challenge to Grubhub trademark win

Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect

Investor's Business Daily

a year ago

Dow Jones Falls As AMD Slides On Downgrade; Nvidia Stock Split Takes Effect

GoldATM Supports Growing Consumer Demand for Gold Purchase with New ATMs in North Carolina

Business Wire

a year ago

GoldATM Supports Growing Consumer Demand for Gold Purchase with New ATMs in North Carolina

GlobeNewswire

a year ago

Middlefield Canadian Income PCC: Net Asset Value(s)

Business Wire

a year ago

Form 8.3 - International Paper Company

Business Wire

a year ago

Net Asset Value(s)

Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval

GlobeNewswire

a year ago

Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval

Global Automotive HMI Market Size To Worth USD 75.3 Billion By 2033 l CAGR 12.36%

GlobeNewswire

a year ago

Global Automotive HMI Market Size To Worth USD 75.3 Billion By 2033 l CAGR 12.36%

RETRANSMISSION: First Hydrogen's FCEV Completes Successful Trial with Amazon

Newsfile

a year ago

RETRANSMISSION: First Hydrogen's FCEV Completes Successful Trial with Amazon

Entrust Enables Governments to Transform Citizen Interactions with Digital Identities

Business Wire

a year ago

Entrust Enables Governments to Transform Citizen Interactions with Digital Identities

MOURI Tech Announces Acquisition of Vertisystem, Enhancing IT Service Offerings and Extending Market Presence

Business Wire

a year ago

MOURI Tech Announces Acquisition of Vertisystem, Enhancing IT Service Offerings and Extending Market Presence

Dstny honored with 'Employee Wellbeing Award'

PR Newswire

a year ago

Dstny honored with 'Employee Wellbeing Award'

Huawei Reveals How to Reach Premium Asian Tourists at Digital Tourist 2024

PR Newswire

a year ago

Huawei Reveals How to Reach Premium Asian Tourists at Digital Tourist 2024

Journal-News, Hamilton, Ohio

a year ago

Retiring ODW executive to be first inductee in Hamilton Business Hall of Fame

Once-in-a-Generation Investment Opportunity: Why You Should Buy Carnival Stock Now

Motley Fool

a year ago

Once-in-a-Generation Investment Opportunity: Why You Should Buy Carnival Stock Now

Cat-sitting startup Meowtel clawed its way to profitability despite trouble raising from dog-focused VCs

TechCrunch

a year ago

Cat-sitting startup Meowtel clawed its way to profitability despite trouble raising from dog-focused VCs

Italian energy company targets Britain for fleet of 20 mini-nukes

The Telegraph

a year ago

Italian energy company targets Britain for fleet of 20 mini-nukes

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy StepStone Group LP (NASDAQ:STEP) For Its Next Dividend

Saudis Said to Hand About 60% of Aramco Offer to Foreigners

Bloomberg

a year ago

Saudis Said to Hand About 60% of Aramco Offer to Foreigners

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?

Simply Wall St.

a year ago

Is Now The Time To Put Planet Fitness (NYSE:PLNT) On Your Watchlist?

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks

Simply Wall St.

a year ago

Don't Buy Banc of California, Inc. (NYSE:BANC) For Its Next Dividend Without Doing These Checks

Genprex to Present at the 2024 BIO International Convention

PR Newswire

a year ago

Genprex to Present at the 2024 BIO International Convention

Genprex dosing subjects in trial of combination therapy for small-cell lung cancer

Clinical Trials Arena

a year ago

Genprex dosing subjects in trial of combination therapy for small-cell lung cancer

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

PR Newswire

a year ago

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors

PR Newswire

a year ago

Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors

Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner

PR Newswire

a year ago

Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner

Sidoti Events, LLC's Virtual May Micro-Cap Conference

ACCESSWIRE

a year ago

Sidoti Events, LLC's Virtual May Micro-Cap Conference

Genprex to Present and Participate at Upcoming May Investor and Industry Conferences

PR Newswire

a year ago

Genprex to Present and Participate at Upcoming May Investor and Industry Conferences

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

PR Newswire

a year ago

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up

Zacks

a year ago

Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

PR Newswire

a year ago

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer

Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System

PR Newswire

a year ago

Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System

Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

PR Newswire

a year ago

Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

PR Newswire

a year ago

Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

PR Newswire

a year ago

Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

PR Newswire

a year ago

Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

PR Newswire

a year ago

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting

Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators

PR Newswire

a year ago

Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators

Genprex to Present at Upcoming BIO CEO & Investor Conference

PR Newswire

a year ago

Genprex to Present at Upcoming BIO CEO & Investor Conference

Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer

PR Newswire

a year ago

Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer

2U Partners with University of Surrey to Launch 15 Online Master's Degrees

PR Newswire

a year ago

2U Partners with University of Surrey to Launch 15 Online Master's Degrees

Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024

PR Newswire

a year ago

Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024

15 Cash-Rich Penny Stocks Hedge Funds Are Buying

Insider Monkey

a year ago

15 Cash-Rich Penny Stocks Hedge Funds Are Buying

OptimizeRx Announces Strategic Board Changes to Support Growth and Evolving Landscape

GlobeNewswire

a year ago

OptimizeRx Announces Strategic Board Changes to Support Growth and Evolving Landscape

Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET

GlobeNewswire

a year ago

Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET

LED Lighting, EV Charging and Electrical Maintenance Provider Orion Announces Preliminary Q3’24 Revenue Growing to $25.8M-$26.2M and Improved Cash Position; Updates FY 2024 Anticipated Revenue Outlook to $90M-$95M

GlobeNewswire

a year ago

LED Lighting, EV Charging and Electrical Maintenance Provider Orion Announces Preliminary Q3’24 Revenue Growing to $25.8M-$26.2M and Improved Cash Position; Updates FY 2024 Anticipated Revenue Outlook to $90M-$95M

Share on Social Networks: